nacresertib (ABBV-848) / Createrna, AbbVie - LARVOL DELTA

A Study to Evaluate How Multiple Doses of Itraconazole Interacts With Nacresertib in Healthy Adult Participants (clinicaltrials.gov) - P1 | N=12 | Active, not recruiting | Sponsor: AbbVie | Recruiting ➔ Active, not recruiting

Enrollment closed

A Study to Evaluate How Multiple Doses of Itraconazole Interacts With Nacresertib in Healthy Adult Participants (clinicaltrials.gov) - P1 | N=12 | Recruiting | Sponsor: AbbVie | Not yet recruiting ➔ Recruiting

Enrollment open

A Study to Assess Adverse Events, Tolerability and How a Single Oral Dose of Nacresertib Moves Through the Body In Healthy Adult Japanese Participants (clinicaltrials.gov) - P1 | N=12 | Completed | Sponsor: AbbVie | Not yet recruiting ➔ Completed

Adverse events • Trial completion

A Study to Evaluate How Multiple Doses of Itraconazole Interacts With Nacresertib in Healthy Adult Participants (clinicaltrials.gov) - P1 | N=12 | Not yet recruiting | Sponsor: AbbVie

New P1 trial

A Study to Assess Adverse Events, Tolerability and How Single and Ascending Oral Doses of Nacresertib Move Through the Body In Healthy Adult Participants (clinicaltrials.gov) - P1 | N=93 | Completed | Sponsor: AbbVie | Active, not recruiting ➔ Completed

Adverse events • Trial completion

Therapeutic Potential of MY004, an IRAK4 Inhibitor, in Psoriasis: Preclinical Activity and Molecular Mechanism (ISDS 2025) - " To evaluate the therapeutic potential of MY004, a selective IRAK4 inhibitor, we used two well-characterized murine psoriasis models: IL-23–induced and imiquimod (IMQ)–induced skin inflammation...Repeat administration of MY004 at high-dose was associated with durable suppression of many disease-marker genes; exploratory comparisons suggested potential durability benefits when evaluated alongside the TYK2 inhibitor BMS-986165. Preclinical data support IRAK4 as a central pathogenic driver of psoriasis and demonstrate that MY004 effectively attenuates psoriatic inflammation through targeted disruption of TLR/IL-1R–dependent signaling. Compared to benchmark therapy, MY004 shows potential for enhanced durability of response, underscoring its promise as a novel therapeutic option in psoriasis."

IO biomarker • Preclinical • Dermatitis • Dermatology • Immunology • Inflammation • Psoriasis • IFNG • IL17A • IL1R1 • IL22 • IL23A • IRAK4 • MYD88 • TNFA • TRAF6 • TYK2

Pharmacokinetic Study of MY004567 Tablets in Patients with Moderate to Severe Active Rheumatoid Arthritis (ChiCTR) - P1 | N=10 | Recruiting | Sponsor: The First Hospital of Jilin University; The First Hospital of Jilin University

New P1 trial • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • CRP